The American Food and Drug Administration (FDA) has approved a new treatment for individuals with early symptomatic Alzheimer's disease

The American Food and Drug Administration (FDA) has now approved the treatment Donanemab for individuals with early symptomatic Alzheimers disease. Donanemab, marketed as Kisunla, has been developed by Eli Lilly and Company. The treatment will be available to patients in the U.S. with mild cognitive impairment (MCI) as well as those with the mild dementia stage of Alzheimer's disease, with confirmed amyloid pathology. The approval of Donanemab follows the two previously approved treatments, Aducanumab and Lecanemab.

In Europe, the European Medicine Agency (EMA) is currently reviewing the treatments Donanemab and Lecanemab.